



"GSK is pursuing a strategy to enhance our manufacturing supply chains and drive access to medicines for patients. Continuous manufacturing is a key part of that strategy," said Mr Mark Buswell, vice-president and head of advanced manufacturing technologies at GSK. "This strategic collaboration allows Pfizer and GSK to align on a vision for PCMM-OSD equipment designs and enables us to deploy flexible, agile and reliable manufacturing solutions to benefit patients."

Pfizer's PCMM technology is a first-of-a-kind manufacturing system that accelerates the speed of tablet production. The pharmaceutical industry has been trending toward lower-volume products, driven by an increased focus on precision medicine approaches to develop and commercialize new therapies. This creates a need for smaller, more flexible continuous processing technologies.

By miniaturizing the equipment, the continuous process can be enclosed in a portable, autonomous space called a POD, which can be transported to any location in the world and quickly assembled.

The PCMM technology has the potential to transform the current biopharmaceutical industry standard of using batch processing to manufacture tablets and capsules from powders-an oftentimes complex process that requires large, dedicated manufacturing facilities. The PCMM continuous process takes only minutes from the addition of raw materials to the completion of finished tablets or capsules.